Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%
This article was originally published in The Pink Sheet Daily
Executive Summary
Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.
You may also be interested in...
Forest’s Ceftaroline Non-inferior To Existing cSSSI Meds In Phase III
Patients receiving antibiotic saw 91.6 percent cure rate.
Forest’s Ceftaroline Non-inferior To Existing cSSSI Meds In Phase III
Patients receiving antibiotic saw 91.6 percent cure rate.
Forest’s Linaclotide, Aclidinium Ready For Phase III
Drugs for constipation and COPD could require extra marketing effort, analysts say.